Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready
Hemarina is active in the Biotechnology & Pharmaceuticals technology area with 1 pending office action. This matter is being reviewed by 1 distinct examiner, RUSSELL G FIEBIG. The prosecution is currently limited to 1 distinct art unit, which suggests a focused technical review process for the company. RUSSELL G FIEBIG is the busiest examiner, responsible for 1 pending office action.
The 1 pending office action represents the total current activity for the company's portfolio. With only 1 distinct examiner and 1 distinct art unit involved, the prosecution path is direct. The busiest examiner's 1 pending office action accounts for all of the entity's current patent office requirements. Practitioners can manage this portfolio with a focus on a single examiner's preferences and a single art unit's standards. This concentration within 1 distinct art unit allows for a specialized legal strategy that addresses the specific nuances of the biotechnology sector as interpreted by the assigned examiner. The data indicates that this single pending office action is the sole focus of the current prosecution cycle.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| FIEBIG, RUSSELL G | 1 | 62.6% | +25.0% |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17995038 | USE OF HAEMOGLOBIN FROM ANNELIDS FOR TREATING ACUTE RESPIRATORY DISTRESS SYNDROME | FIEBIG, RUSSELL G | — |
| Art Unit | Apps |
|---|---|
| 1655 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 17995038 | USE OF HAEMOGLOBIN FROM ANNELIDS FOR TREATING ACUTE RESPIRATORY DISTRESS SYNDROME | FIEBIG, RUSSELL G | 1655 | §103 | Non-Final OA | — | Pending | Sep 29, 2022 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial